# A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

> **NCT05156268** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Endometrial Carcinosarcoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05156268
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-27
- **Primary completion:** 2026-04-24
- **Final completion:** 2026-04-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156268, "A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05156268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*